Limited data exists on COVID-19 mRNA vaccine
effectiveness in children aged 1–4 years, particularly against Omicron
subvariants. In a cohort study conducted during Omicron XBB subvariant
predominant period in Singapore, completing the primary COVID-19 mRNA vaccine
series significantly protected against COVID-19 infection in this age group,
with 45.2% and 63.3% vaccine effectiveness in partially and fully vaccinated
children, respectively. Vaccine effectiveness was also robust at 74.6% in
children with prior COVID-19 infection who received at least one vaccine dose.
The WHO defines long COVID as a condition that occurs 3 months from COVID-19 onset, whose symptoms last ≥2 months and cannot be attributed to an alternative diagnosis. In an interview with MIMS Doctor, Professor Ghassan Dbaibo of the Center for Infectious Diseases, American University of Beirut, Beirut, Lebanon, describes the evolving attitudes towards long COVID among healthcare professionals (HCPs), some unexpected predisposing factors, potential biological mechanisms behind prolonged symptom duration and shares data on vaccination’s protective effects against long COVID.
Executive function (EF) skills in childhood predict academic success better than a child’s intelligence quotient (IQ), and are associated with better physical health, more stable careers, and higher socioeconomic status in adulthood. [Psychol Sci 2005;16:939-944; J Clin Psychiatry 2012;73:941-950; Pediatrics 2013;131:637-644] Despite this, EF is an important topic that is often overlooked. To learn more about EF, MIMS Doctor interviewed Dr Evelyn Law, a clinician scientist specialising in developmental and behavioural paediatrics. Dr Law is Assistant Professor at the National University of Singapore Yong Loo Lin School of Medicine, Singapore.
Assoc Prof. Louis Grandjean, Adj Asst Prof. Natalie Tan, 20220701000000
The management of multidrug-resistant (MDR) infections in children is complex, with limited studies and a relative lack of approved new antibiotics with paediatric indications.
At a recent Meet-the-Expert session, Dr Louis Grandjean, Consultant in Paediatric Infectious Diseases at Great Ormond Street Hospital and Associate Professor at University College, London, UK, addressed the growing threat of MDR infections in children and discussed treatment strategies and options for management. He focused on ceftazidime-avibactam (CAZ-AVI, Zavicefta®), whose approval in Singapore was recently expanded to include paediatric patients aged 3 months and older.
Adj Asst Prof Natalie Tan, Senior Consultant at KK Women’s and Children’s Hospital, Singapore, chaired this webinar, which was organized by Pfizer under the auspices of the Singapore Paediatric Society and KK Women’s and Children’s Hospital.
Allergic rhinitis is the most frequently occurring form of allergy in
the world. It has a high burden in childhood, affecting sleep, concentration,
and consecutively, learning. Professor Nikolaos Papadopoulos delivered a
lecture on the evidence base and clinical experience supporting the use of
Bilastine in children at the 11th Singapore Sleep, Allergy and Rhinology
conference on 1 October 2020.
Allergic rhinitis can induce two types of
symptoms in patients: i) histamine-mediated symptoms such as vasodilatation,
rhinorrhoea, itching and sneezing, and ii) allergic inflammation resulting from
the action of eosinophils in the nasal lining. H1-antihistamine therapy is a
mode of therapy that seeks to mitigate the histamine-mediated symptoms of allergic
rhinitis; this therapy aims to relieve symptoms and to improve quality of
life in patients.
A large retrospective study from the US, presented at IDWeek 2021, has shown that the Abbott ID NOW rapid molecular COVID-19 assay is highly sensitive and specific at detecting SARS-CoV-2 infection in a paediatric population.